Mark J. Ingerman
- Infectious Diseases top 10%
- Pharmacology top 10%
- Molecular Medicine top 5%
- Clinical Biochemistry top 5%
- Epidemiology
- Co-authors
- Jerome SantoroMatthew E. LevisonP. G. PitsakisElías AbrutynAlexander F. RosenbergD. ChurchB E MurrayAudrey Wanger
- Topics
- Antibiotics Pharmacokinetics and Efficacy (5 papers)Antimicrobial Resistance in Staphylococcus (4 papers)Bacterial Identification and Susceptibility Testing (3 papers)
- Journals
- SHILAP Revista de lepidopterologíaThe Journal of Infectious DiseasesAntimicrobial Agents and Chemotherapy
- Partner nations
- United StatesCanada
In The Last Decade
Mark J. Ingerman
10 papers receiving 340 citations
Peers
Comparison fields: 5 of 65
- Infectious Diseases 191
- Pharmacology 146
- Molecular Medicine 117
- Clinical Biochemistry 110
- Epidemiology 106
Countries citing papers authored by Mark J. Ingerman
This map shows the geographic impact of Mark J. Ingerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Ingerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Ingerman more than expected).
Fields of papers citing papers by Mark J. Ingerman
This network shows the impact of papers produced by Mark J. Ingerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Ingerman. The network helps show where Mark J. Ingerman may publish in the future.
Co-authorship network of co-authors of Mark J. Ingerman
This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Ingerman. A scholar is included among the top collaborators of Mark J. Ingerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Ingerman. Mark J. Ingerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 6 | |
| 3 | 32 | |
| 4 | 10 | |
| 5 | Vancomycin. A new old agent. | 30 |
| 6 | 26 | |
| 7 | 58 | |
| 8 | Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. | 48 |
| 9 | 87 | |
| 10 | 49 |
About Mark J. Ingerman
Mark J. Ingerman is a scholar working on Clinical Biochemistry, Molecular Medicine and Pharmacology, having authored 10 papers that have together received 357 indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers) and Bacterial Identification and Susceptibility Testing (3 papers). The work is most often cited by research in Molecular Medicine (117 citations), Clinical Biochemistry (110 citations) and Applied Microbiology and Biotechnology (27 citations). Mark J. Ingerman has collaborated with scholars based in United States and Canada. Frequent co-authors include Jerome Santoro, Matthew E. Levison, P. G. Pitsakis, Elías Abrutyn, Alexander F. Rosenberg, D. Church, B E Murray, Audrey Wanger, Lawrence L. Livornese and Robert L. Benz. Their work appears in journals such as SHILAP Revista de lepidopterología, The Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.